N@N

Rochea?s New RTCA Cardio Instrument for Label-Free Functional Cardiomyocyte Toxicity Testing

_{//health-fitness.news-articles.net/content/2010/ .. e-functional-cardiomyocyte-toxicity-testing.html}
^{Published in Health and Fitness on Tuesday, September 28th 2010 at 5:10 GMT by Market Wire}  

PENZBERG, Germany--([ BUSINESS WIRE ])--Roche [ (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) ] announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium-throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time. The instrument features a unique detection rate and frequency measurement concept as well as dedicated software features. Unlike synergistic techniques such as patch clamp, the new system can be used in a fully controlled environment for continuous short-term and long-term experiments, thus increasing the applicable experimental time as well as reproducibility and data quality.

"There is a clear need and technology gap for cell-based analysis platforms and real-time, label-free technologies"

Cardiotoxicity is one of the most relevant parameters tested in drug development. The RTCA Cardio Instrument is the only 96 well, cardiotoxicity screening system on the market for continuous, real-time, label-free cardiomyocyte beating analysis. The instrument can be used in conjunction with cardiomyocytes derived from human or mouse stem cells for assessing the cardiac safety profile of lead compounds or drug candidates during drug development.

aThere is a clear need and technology gap for cell-based analysis platforms and real-time, label-free technologies,a says Ruedi Stoffel, Life Cycle Leader Cellular Analysis at Roche Diagnostics. aThe patch clamp techniques currently in use offer only a small glimpse at certain ion channels over the course of a few hours preceding cell death. The RTCA Cardio Instrument provides online beating pattern analysis for Quality Control and standardized conditions, as well as for short-term and long-term experiments.a

The xCELLigence system provides a non-invasive, label-free way to continuously monitor cellular parameters such as viability, death, adhesion and proliferation. The system records the electrical impedance of cells grown on microelectrode arrays integrated into the bottom of each well of an E-Plate 96. Cell-sensor impedance is expressed as the Cell Index (CI), and changes in CI correlate to modifications in cell morphology. Use of the new RTCA Cardio Instrument will be especially high in pharmaceuticals research, pre-clinical safety testing and analysis for cardiac research.

More information please find at [ www.xcelligence.roche.com ].

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the worlda™s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Rochea™s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: [ www.roche.com ].

For life science research only. Not for use in diagnostic procedures.

XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US
Other brands or product names are trademarks of their respective holders.